Xtant Medical (NYSEAMERICAN:XTNT) Stock Crosses Above 200-Day Moving Average – What’s Next?

Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.54. Xtant Medical shares last traded at $0.54, with a volume of 91,934 shares traded.

Xtant Medical Stock Up 12.5 %

The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42. The company’s fifty day moving average price is $0.54. The stock has a market capitalization of $75.07 million, a price-to-earnings ratio of -4.15 and a beta of 0.35.

Hedge Funds Weigh In On Xtant Medical

An institutional investor recently raised its position in Xtant Medical stock. Geode Capital Management LLC increased its stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 515,006 shares of the medical device company’s stock after purchasing an additional 212,394 shares during the quarter. Geode Capital Management LLC owned 0.37% of Xtant Medical worth $348,000 at the end of the most recent quarter. 69.33% of the stock is currently owned by institutional investors.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.